Drug Trial Radar · NCT07468071
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Actual
Start
Jun 8, 2026
Primary completion
Jun 11, 2029
Study completion Sep 11, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
Conditions
- Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
- Advanced Solid Tumors Harboring the KRAS G12C Mutation
Interventions
OpnurasibDrug
Eligible participants will receive the same starting dose and regimen of opnurasib as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.
TNO155Drug
Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.
trametinibDrug
Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.
cetuximabBiological
Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.
tislelizumabBiological
Eligible participants will receive the same starting dose and regimen of any applicable combination drug as the last dose and regimen administered before completing the parent protocol at the time of transition to the rollover study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants receiving opnurasib as single agent or in combination with other study treatmentsTime frame: Assessed up to approximately 3 years
- Duration of exposure to study treatmentTime frame: Assessed up to approximately 3 years
Locations
21 sites in 10 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Sint-Niklaas, Oost Vlaanderen, Belgium
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Koto Ku, Tokyo, Japan
Novartis Investigative Site
Kuching, Sarawak, Malaysia
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.